

Sai Life Sciences expands suite of cellular analysis platforms

11 September 2020 | News

Enabling it to better serve start-up and biotech companies



Hyderabad based Sai Life Sciences, one of India's fastest growing Contract Development & Manufacturing Organizations (CDMOs), has announced the addition of state-of-the-art cellular analysis platforms at its [Discovery Biology facility in Cambridge, Massachusetts, USA](#).

Coinciding with its first anniversary in Cambridge, the expanded suite of capabilities include the Opera Phenix high content screening platform, FACSCelesta flow cytometer and FACSMelody flow sorter, enabling it to better serve start-up and biotech companies in the region, especially in projects exploring novel biology in oncology, neuroscience and rare diseases.

Over the past year, the lab has delivered a range of projects including genetic and pharmacological target validation studies, reagent validation, and developed a variety of assays for its clients, such as cellular target engagement assays and in vitro biomarker assessments.

Speaking about the company's plans, CEO & Managing Director of Sai Life Sciences, **Krishna Kanumuri** said, "*We are committed to helping our clients successfully advance their internal discovery portfolios and are investing considerable resources to provide world-class service in the Boston area. These new capability additions are just the latest in our strategic growth plan with significant additional capabilities coming soon.*"

The Cambridge lab serves as a vital bridge, enabling seamless integration with rest of the company's service offerings across UK and India, spanning the drug discovery and development continuum including medicinal chemistry, DMPK and toxicology, process chemistry and analytical development, and commercial scale manufacturing.